YWYimei Wei

Yimei Wei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yimei Wei has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Baofu Zhang

    Institute of Communications Engineering, PLA University of Science and Technology, Nanjing, China 210017

    1 shared publication
  • Bo Zhu

    Department of Mathematics, Texas A&M University, Blocker Building, 3368 TAMU, 155 Ireland Street, College Station, Texas 77840

    1 shared publication
  • Chuanxin Wu

    PLA University of Science and Technology

    1 shared publication
  • Dandan Wang

    Department Geriatrics Chongqing General Hospital Chongqing China

    1 shared publication
  • Jie Zhang

    Department of Geriatrics, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, No. 118, Xingguang Avenue, Liangjiang New Area, Chongqing 401147, China

    1 shared publication
  • Juan Wu

    Department Geriatrics Chongqing General Hospital Chongqing China

    1 shared publication

Latest Publications

  • JAK2 inhibitors improve RA combined with pulmonary fibrosis in rats by downregulating SMAD3 phosphorylation

    by Yimei Wei, Dandan Wang, Juan Wu, Jie Zhang

    Background: JAK inhibitors are well known for the treatment of rheumatoid arthritis (RA), but whether they can be used to treat pulmonary fibrosis, a common extra‐articular disease of RA, remains to be clarified.Methods: A jak2 inhibitor, CEP33779 (CEP), was administered to a rat model of RA‐associated interstitial lung disease to observe the degree of improvement in both joint swelling and pulmonary fibrosis. HFL1 cells were stimulated with TGF‐β1 to observe the expression of p‐JAK2. Then, different concentrations of related gene inhibitors (JAK2, TGFβ‐R1/2, and p‐STAT3) or silencers (STAT3, JAK2) were administered to HFL1 cells, and the expression levels of related proteins were detected to explore the underlying mechanisms of action.Results: CEP not only reduced the degree of joint swelling and inflammation in rats but also improved lung function, inhibited the pro‐inflammatory factors IL‐1β and IL‐6, reduced lung inflammation and collagen deposition, and alleviated lung fibrosis. CEP decreased the expression levels of TGFβ‐R2, p‐SMAD, p‐STAT3, and ECM proteins in rat lung tissues. TGF‐β1 induced HFL1 cells to highly express p‐JAK2, with the most pronounced expression at 48 h. The levels of p‐STAT3, p‐SMAD3, and ECM‐related proteins were significantly reduced after inhibition of either JAK2 or STAT3.Conclusion: JAK2 inhibitors may be an important and novel immunotherapeutic drug that can improve RA symptoms while also delaying or blocking the development of associated pulmonary fibrotic disease. The mechanism may be related to the downregulation of p‐STAT3 protein via inhibition of the JAK2/STAT signaling pathway, which affects the phosphorylation of SMAD3.


  • A Quick Method of Measuring the Transmission Time of Optical Fiber

    by Bo Zhu, Yong Zhu, Lin Lu, Baofu Zhang, Chuanxin Wu, Yimei Wei, Longqiang Yu